Evidence map›Paper›PMID 25920556›Full record

ArticleEuropean journal of human genetics : EJHG2016

Attitudes of nearly 7000 health professionals, genomic researchers and publics toward the return of incidental results from sequencing research.

Anna Middleton, Katherine I Morley, Eugene Bragin, Helen V Firth, Matthew E Hurles, Caroline F Wright, Michael Parker, DDD study

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
123citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

123 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Returning Incidental Research Findings FromArthritis care & research · 2024
    Article
  18. Article
  19. Article
  20. Article

63 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anna MiddletonWellcome Trust Sanger Institute, Human Genetics, Cambridge, UK.ORCID http://orcid.org/0000-0003-3103-8098
Katherine I MorleyAddictions Department, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, UK.
Eugene BraginWellcome Trust Sanger Institute, Human Genetics, Cambridge, UK.
Helen V FirthDepartment of Clinical Genetics, Addenbrooke's Hospital, Cambridge, UK.
Matthew E HurlesWellcome Trust Sanger Institute, Human Genetics, Cambridge, UK.
Caroline F WrightWellcome Trust Sanger Institute, Human Genetics, Cambridge, UK.
Michael ParkerThe Ethox Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK.
DDD study

Funding

Department of HealthWellcome Trust
6 · The paper itself

Abstract

Genome-wide sequencing in a research setting has the potential to reveal health-related information of personal or clinical utility for the study participant. There is increasing pressure to return research findings to participants that may not be related to the project aims, particularly when these could be used to prevent disease. Such secondary, unsolicited or 'incidental findings' (IFs) may be discovered unintentionally when interpreting sequence data, or as the result of a deliberate opportunistic screen. This cross-sectional, web-based survey investigated attitudes of 6944 individuals from 75 countries towards returning IFs from genome research. Participants included four relevant stakeholder groups: 4961 members of the public, 533 genetic health professionals, 843 non-genetic health professionals and 607 genomic researchers who were invited via traditional media, social media and professional e-mail list-serve. Treatability and perceived utility of incidental results were deemed important with 98% of stakeholders personally interested in learning about preventable life-threatening conditions. Although there was a generic interest in receiving genomic information, stakeholders did not expect researchers to opportunistically screen for IFs in a research setting. On many items, genetic health professionals had significantly more conservative views compared with other stakeholders. This finding demonstrates a disconnect between the views of those handling the findings of research and those participating in research. Exploring, evaluating and ultimately addressing this disconnect should form a priority for researchers and clinicians alike. This social sciences study offers the largest dataset, published to date, of attitudes towards issues surrounding the return of IFs from sequencing research.

Indexed as

AttitudeGenome, HumanAdultChromosome MappingCross-Sectional StudiesExomeFemaleGenetic PrivacyHigh-Throughput Nucleotide SequencingHumansIncidental FindingsInformation DisseminationInformed ConsentMaleMiddle AgedPrecision Medicine

Identifiers

PMID25920556
PMCPMC4795240

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.